{
    "2021-09-27": [
        [
            {
                "time": "",
                "original_text": "医药生物行业周报：从景气度、竞争力、外需逻辑看诺禾致源投资价值",
                "features": {
                    "keywords": [
                        "医药生物",
                        "景气度",
                        "竞争力",
                        "外需",
                        "诺禾致源",
                        "投资价值"
                    ],
                    "sentiment_score": 0.75,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "医药生物"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "",
                "original_text": "集采降价预期见底企稳回升，建议超配生物医药板块",
                "features": {
                    "keywords": [
                        "集采",
                        "降价",
                        "预期见底",
                        "企稳回升",
                        "生物医药",
                        "超配"
                    ],
                    "sentiment_score": 0.8,
                    "policy_related": "true",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "生物医药"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            }
        ]
    ]
}